Format

Send to

Choose Destination
Transfus Clin Biol. 2017 Sep;24(3):273-276. doi: 10.1016/j.tracli.2017.06.013. Epub 2017 Jun 29.

In vitro generation of platelets: Where do we stand?

Author information

1
Department of molecular medicine, university of Pavia, Pavia, Italy; Biotechnology, research laboratories, IRCCS San Matteo Foundation, Pavia, Italy.
2
Department of biomedical engineering, Tufts university, Medford, MA, USA.
3
Department of molecular medicine, university of Pavia, Pavia, Italy; Biotechnology, research laboratories, IRCCS San Matteo Foundation, Pavia, Italy; Department of biomedical engineering, Tufts university, Medford, MA, USA. Electronic address: alessandra.balduini@unipv.it.

Abstract

Millions of platelets, specialized cells that participate in haemostatic and inflammatory functions, are transfused each year worldwide, but their supply is limited. Platelets are produced by megakaryocytes by extending proplatelets, directly into the bloodstream. Bone marrow structure and extracellular matrix composition together with soluble factors (e.g. Thrombopoietin) are key regulators of megakaryopoiesis by supporting cell differentiation and platelet release. Despite this knowledge, the scarcity of clinical cures for life threatening platelet diseases is in a large part due to limited insight into the mechanisms that control the developmental process of megakaryocytes and the mechanisms that govern the production of platelets within the bone marrow. To overcome these limitations, functional human tissue models have been developed and studied to extrapolate ex vivo outcomes for new insight on bone marrow functions in vivo. There are many challenges that these models must overcome, from faithfully mimicking the physiological composition and functions of bone marrow, to the collection of the platelets generated and validation of their viability and function for human use. The overall goal is to identify innovative instruments to study mechanisms of platelet release, diseases related to platelet production and new therapeutic targets starting from human progenitor cells.

KEYWORDS:

3D models; Bioreactor; Bioréacteur; Megakaryocytes; Modèles 3D; Mégacaryocytes; Plaquettes; Platelets; Thrombocytopenia; Thrombopénie; Transfusion

PMID:
28669522
PMCID:
PMC6081495
DOI:
10.1016/j.tracli.2017.06.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center